Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma

Figure 6

The prediction efficacy of immunotherapy based on the risk score. (a) KM curve for high- and low-risk subgroups in the anti-PD-L1 and anti-CTLA4 cohort (GSE91061). (b) The proportion of immune response (CR: complete response; PR: partial response; SD: stable disease; and PD: progressive disease) between two groups in GSE91061. (c) ROC analysis of the risk score on the response rate in GSE91061. (d) KM curve for high- and low-risk subgroups in the anti-PD-L1 (GSE78220). (e) The proportion of immune response (CR, PR, SD, and PD) between two groups in GSE78220. (f) ROC analysis of the risk score on the response rate in GSE78220. (g) ROC analysis of the risk score, MSI, and TIDE on OS at 1-, 2-, and 3-year follow-up in GSE91061. (h) ROC analysis of the risk score, MSI, and TIDE on OS at 1-, 1.5-, and 2.5-year follow-up in GSE78220.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)